🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "huge turning point" in the effort against superbug strains of the pathogen, according to scientists.

A Global Public Health Issue

The sexually transmitted infection are escalating globally, with estimates suggesting more than 82 million new cases annually. Notably increased rates are reported in the African continent and nations within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have reached a all-time high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune advancement in the face of increasing worldwide cases, the spread of superbugs and the extremely scarce treatment choices presently on offer.”

Health officials are increasingly worried about the rise in treatment-resistant strains. The global health body has classified it as a "high-priority threat". Recent surveillance showed that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Secure Clearance

Zoliflodacin, also known as Nuzolvence, was cleared by the US FDA in mid-December for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Experts hope that focused deployment of this new drug will help slow the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in the same week. This medication, which is also used to treat UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a innovative non-profit model for drug creation. The non-profit organisation GARDP partnered with the drug firm Innoviva to develop it.

“This milestone represents a huge turning point in the management of superbug gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Testing Results and Global Access

Based on results released by a major medical journal, the new drug successfully treated over nine in ten of uncomplicated infections. This places it at an similar efficacy with the existing first-line therapy, which uses a dual-drug approach. The trial involved over 900 participants from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, the non-profit has the rights to license and sell the drug in numerous low-income and middle-income countries.

Medical professionals treating patients have shared hope. The availability of a easy-to-administer therapy such as this is described as a "critical tool" for managing the epidemic. This is considered vital to alleviate the strain of the illness for individuals and to prevent the spread of extremely resistant gonorrhoea around the world.